What were Syncom Healthcare Ltd's latest quarterly results?
Syncom Healthcare Ltd's latest quarterly results (Jun 2021) show
- PAT Growth YoY: +26.0%
- Revenue Growth YoY: +9.4%
- Operating Margin: -225.7%
Syncom Healthcare Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. ROE: -152.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Syncom Healthcare Ltd's latest quarterly results (Jun 2021) show
Syncom Healthcare Ltd's price-to-book ratio is 4.7x.
Syncom Healthcare Ltd's fundamental strength based on key financial ratios
Syncom Healthcare Ltd has a debt-to-equity ratio of N/A.
Syncom Healthcare Ltd's return ratios over recent years
Syncom Healthcare Ltd's operating cash flow is negative (FY2023).
Syncom Healthcare Ltd currently does not pay a significant dividend (yield 0.00%).
Syncom Healthcare Ltd's shareholding pattern (Jun 2021)
Syncom Healthcare Ltd's promoter holding has remained stable recently.
Syncom Healthcare Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Syncom Healthcare Ltd may be worth studying
Syncom Healthcare Ltd investment thesis summary:
Syncom Healthcare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.